Market News & Trends
Quris Closes Critical Drug Development Gaps With New Clinical Prediction AI Platform
Quris recently launched the first clinical prediction AI platform to predict which drug candidates will safely work in humans – significantly improving efficacy and cutting drug development….
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Phathom Pharmaceuticals, Inc. recently announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal Phase 3 trial evaluating….
Menarini Group & Radius Health Announce Positive Phase 3 Topline Results From the EMERALD Trial Evaluating Elacestrant in Breast Cancer
The Menarini Group and Radius Health, Inc. recently announced positive topline results from the EMERALD study. The study was designed to evaluate elacestrant as a….
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Athira Pharma, Inc. recently announced it has completed enrollment in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease.…
HistoWiz Raises $32-Million Financing to Fully Automate Lab Operations, Launch New AI-Enabled Services & Establish a GLP Histopathology Lab in Miami
HistoWiz, a leading digital histopathology service company, recently announced the closing of a $32-million Series A financing. The company has provided automated histology for over…
Interpace Diagnostics Announces US Patent Approval: MicroRNAs as Biomarkers for Distinguishing Benign From Malignant Thyroid Neoplasms
Interpace Biosciences, Inc. recently announced the United States Patent and Trademark Office granted it a Patent (US PTO Number 11,118,231 B2) for use of microRNAs…
MatriSys Announces Positive Results from a Study of S. felis for the Treatment of Drug-Resistant S. pseudintermedius
MatriSys Bioscience recently announced the publication of research on a strain of Staphylococcus felis (S. felis C4) isolated from feline skin for the treatment of Methicillin-resistant…
reMYND’s ReS19-T Program, Managing Calcium Homeostasis for Alzheimer’s, Has Moved to MAD Phase After Demonstrating Strong Safety in SAD Phase
reMYND NV recently announce it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in…
Pfizer & BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Pfizer Inc. and BioNTech SE recently announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of…
Tjoapack expands Into US With Acquisition of Pharma Packaging Solutions
Tjoapack recently announced it has acquired US-based Pharma Packaging Solutions (PPS), a leading healthcare packaging services business based in Clinton, TN. PPS provides commercial packaging…
Silence Therapeutics Provides mRNAi GOLD Platform & Pipeline Updates
Silence Therapeutics plc, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with…
Credence MedSystems Announces Strategic Collaboration With Phillips Medisize
Credence MedSystems, Inc. recently announced it has formed a strategic collaboration with Phillips-Medisize, a Molex company, a global leader in the design and manufacturing of solutions for the pharmaceutical drug delivery market…..
A New Study Using the SomaScan Platform Makes the Connection Between Genes & Proteins & Their Impact on Human Disease
In the largest proteogenomic study of its kind to date, an international research team led by scientists at the Berlin Institute of Health at Charité…
Ferrer & Treeway Enter License Agreement for the Development & Commercialization of TW001/FNP122 for Amyotrophic Lateral Sclerosis
Ferrer and Treeway recently announced they have entered into a licence agreement for the development and commercialization of an oral formulation of edaravone (TW001/FNP122) for Amyotrophic…
OliX Pharmaceuticals Enters Agreement With Pharmaron to Advance Non-Clinical Toxicology Testing for Hepatitis B Candidate
OliX Pharmaceuticals, Inc. recently announced it has selected Pharmaron, a leading contract research organization based in China, to conduct non-clinical toxicity studies to evaluate the…
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety & Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate
Emergent BioSolutions Inc. recently announced the first participant dosed in its pivotal Phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya…
CEL-SCI’s Multikine Immunotherapy Produces Significant Survival Benefit in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head & Neck Cancer Phase 3 Study
CEL-SCI Corporation recently announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine (Leukocyte Interleukin, Injection)* in the treatment of advanced…
Evonik Launches Next-Generation LIPEX Extruder for Fast & Effective Liposomal Drug Manufacturing
Evonik has launched a new version of its industry renowned drug manufacturing equipment LIPEX liposome extruders. LIPEX Flow, which is available worldwide from November 2021,…
Ascendia Once Again Ranked on Inc. 5000 List of America’s Fastest-Growing Private Companies
Inc. magazine revealed that Ascendia Pharmaceuticals rose 3,239 positions on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies…..
Viridian Therapeutics Submits IND Application for an IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Viridian Therapeutics, Inc. recently announced the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA). The company…
